Nevro

What Nevro does

Nevro is a US-based medical device company that develops and commercializes spinal cord stimulation (SCS) systems for the treatment of chronic intractable pain. Its core technology, 10 kHz Therapy, delivers high-frequency neuromodulation that provides pain relief without the paresthesia associated with traditional low-frequency SCS, and is delivered through the Senza, Senza Omnia, and HFX iQ implantable platforms. The HFX iQ system, launched in September 2024 with HFX AdaptivAI, was the first FDA-cleared AI-enabled SCS system and adds big-data-driven therapy personalization and remote physician monitoring. Nevro also sells a portfolio of sacroiliac (SI) joint fusion devices (Nevro1, SICONUS, VYRSA Pro) acquired through the 2023 purchase of Vyrsa Technologies, broadening the franchise into the US SI joint fusion market.

The company sells primarily to healthcare providers and hospital systems through a direct enterprise field-sales motion, supported by the HFX Access program for prior authorization and reimbursement navigation and by a clinical evidence base that includes landmark studies such as SENZA-RCT and SENZA-PDN. Revenue is generated through one-time hardware sales of implantable pulse generators, leads, and accessories, with pricing not publicly disclosed and reimbursement secured through Medicare and major commercial plans covering HFX therapy. Nevro holds FDA-approved indications unique to its HFX system for painful diabetic neuropathy (PDN) and non-surgical refractory back pain (NSRBP), and is protected by an IP portfolio of over 150 US patents.

Nevro was founded in 2007 (firmographics list 2006) and was publicly traded on the NYSE under NVRO until Q2 2025, when it was acquired by Globus Medical for $250 million. It now operates as a wholly-owned subsidiary within Globus's musculoskeletal solutions portfolio, with regional operating entities in the US, Australia, Germany, the UK, Switzerland, and Costa Rica, and contributed approximately $99.7 million in Q4 2025 sales to its parent.

Name

Nevro

Legal name

Nevro Corp.

Website

https://nevro.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Nevro is a US-based medical device company (now a Globus Medical subsidiary) that develops and sells spinal cord stimulation systems, including the FDA-cleared AI-enabled HFX iQ platform, alongside SI joint fusion devices, serving physicians, hospitals, and chronic pain patients globally.

Ownership category

akta.pro rank

Product category

Neuromodulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

akta.pro secondary industry

Spine (Orthopedic Spine) (HLAKALAE)

Keywords

• Spinal cord stimulation devices
• Chronic pain management
• Neuromodulation therapy
• Sacroiliac joint fusion
• Medical device implants

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Spinal Cord Stimulation Devices: Sale of implantable medical devices including Senza, Senza Omnia, Nevro1, and HFX iQ spinal cord stimulation systems. These are capital equipment purchases involving the implantable pulse generator, leads, and accessories. Revenue is generated through one-time device sales to healthcare providers and hospital systems.
2. Sacrum and SI Joint Fusion Products: Sale of sacroiliac joint fusion and fixation devices including Nevro1, SICONUS, and VYRSA product lines acquired through the Vyrsa Technologies acquisition. Products include implants for SI joint fusion procedures.
3. Physician Training and Support Services: HFX Services and Support including physician training, clinical support, and reimbursement assistance through the HFX Access patient access program.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Nevro develops and manufactures implantable spinal cord stimulation (SCS) systems under the HFX platform, featuring its proprietary 10 kHz Therapy (HF10) and the AI-enabled HFX iQ system with HFX AdaptivAI. The company also produces minimally invasive sacroiliac (SI) joint fusion devices (Nevro1, SICONUS, VYRSA Pro) and supports patients and providers through the HFX Access reimbursement and prior authorization program.

Product overview

Nevro is a medical device company offering HFX, a comprehensive solution for individualized chronic pain relief. The core portfolio includes the Senza/Senza Omnia spinal cord stimulation systems featuring proprietary 10 kHz Therapy, the AI-powered HFX iQ system with HFX AdaptivAI technology, and the acquired Vyrsa product line for sacroiliac joint fusion (Nevro1, SICONUS, VYRSA Pro). The HFX platform spans multiple FDA-approved indications including chronic trunk and limb pain, painful diabetic neuropathy (PDN), and non-surgical refractory back pain (NSRBP), supported by the HFX Access patient reimbursement program. Nevro was acquired by Globus Medical in Q2 2025.

Differentiator

Problem solved

Functional benefit

Brands

• HFX: Comprehensive solution for individualized relief of chronic pain, including the HFX iQ AI-powered spinal cord stimulation system and HFX AdaptivAI technology
• Senza
• Senza Omnia
• Nevro1
• NevroFix
• NevroPro
• HFX Access
• Vyrsa Technologies

Products and services

• HFX iQ AI-powered spinal cord stimulation system with HFX AdaptivAI technology that provides personalized chronic pain relief by leveraging big data and real-time patient inputs to optimize therapy delivery, intended for healthcare providers who implant SCS devices.
• Senza Omnia FDA-approved spinal cord stimulation system capable of delivering all available SCS frequencies and the most waveform types in a single product, enabling long-term pain relief for chronic pain patients.
• Senza Original Nevro SCS system that pioneered 10 kHz Therapy, providing patients with significant chronic pain relief without paresthesia (tingling sensation).
• 10 kHz Therapy Nevro's proprietary high-frequency spinal cord stimulation therapy operating at 10 kHz, providing chronic pain relief without the paresthesia associated with traditional low-frequency stimulation.
• Nevro1 Sacroiliac (SI) Transfixing and Fusion System intended for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis.
• HFX Trial Stimulator Trial version of Nevro's spinal cord stimulation system used to evaluate patient response to SCS therapy before permanent implantation.
• SICONUS SI Joint Fixation System Intended to provide fixation and stabilization of large bones, including the sacrum and ilium, as an adjunct to sacroiliac joint fusion in the treatment of degenerative sacroiliitis or sacroiliac joint disruptions.
• VYRSA Pro SI Fusion Spacer SI Fusion Spacer for fracture fixation of large bones and large bone fragments of the pelvis, used with autologous bone graft via open or minimally invasive posterior approach.
• HFX for PDN Senza spinal cord stimulation system programmed to include a frequency of 10 kHz specifically for the management of chronic intractable pain of the lower limbs associated with diabetic neuropathy.
• HFX for Non-Surgical Back Pain Spinal cord stimulation therapy indicated for the management of non-surgical refractory back pain (intractable back pain without prior surgery and not a candidate for back surgery).
• HFX Access Patient access program that assists patients in navigating the prior authorization process for HFX SCS Therapy, including prior authorization support, pre-determination, denial support, and billing/coding/coverage assistance.

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Partnerships

One partnership is on record.

• Vyrsa TechnologiescoreStrategic or Co-development Partner · 30 November 2023Nevro acquired Vyrsa Technologies, a medical technology company specializing in minimally invasive treatments for sacroiliac joint pain, for up to $75 million. The acquisition expanded Nevro's portfolio to include SI joint fusion devices and strengthened its position in the over $2 billion US SI joint fusion market.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Medtronic: Medtronic is the largest neuromodulation player globally, offering competing SCS systems (Intellis with Vanta, WaveWriter Alpha) for chronic pain. Direct competitor to Nevro's Senza/HFX platform in the same physician call points and payer landscape.
• Boston Scientific: Boston Scientific's WaveWriter Alpha SCS systems compete head-to-head with Nevro's Senza Omnia and HFX iQ in the pain specialist channel, with overlapping indications and reimbursement positioning.
• Abbott: Abbott's Proclaim SCS and BurstDR platforms are direct competitors to Nevro's SCS systems, leveraging similar physician networks and reimbursement pathways for chronic pain indications.
• SI-Bone: SI-Bone is the dominant pure-play in minimally invasive SI joint fusion with its iFuse implant system, directly competing with Nevro's Vyrsa-acquired Nevro1, SICONUS, and VYRSA Pro portfolio.

Broad incumbents

• Globus Medical: Globus Medical acquired Nevro in Q2 2025 and is now its parent. As a musculoskeletal incumbent with a broad spine and orthopedic portfolio, Globus provides the cross-sell channel and commercial scale behind Nevro's SCS and SI joint products.
• Stryker: Stryker is a broad orthopedic and spine incumbent with interventional pain management offerings; comparable as a large platform player operating adjacent to Nevro's pain specialist channel and competing for hospital budgets.
• Zimmer Biomet: Zimmer Biomet operates broadly in spine and orthopedic implants with adjacent interventional pain offerings, providing a comparable orthopedic scale player reference for Nevro's spine-adjacent business.

Emerging players

• Axonics: Axonics develops implantable neuromodulation devices (primarily sacral neuromodulation for incontinence), sharing the implantable pulse generator technology stack and regulatory pathway expertise relevant to SCS, but addressing different indications.
• Inspire Medical Systems: Inspire Medical Systems is a neuromodulation peer focused on obstructive sleep apnea, using an implantable neurostimulation device. Comparable as a high-growth implantable neuromodulation specialist, though addressing a different clinical indication.
• Mainstay Medical: Mainstay Medical develops the ReActiv8 implantable neurostimulation system for chronic low back pain, a direct indication overlap with Nevro's NSRBP-focused HFX therapy and an emerging competitor in restorative neuromodulation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/NevroHFX
• LinkedInlinkedin.com/company/nevro-hfx
• Xx.com/nevro_hf10

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries5 records

Funding overview

Funding rounds7 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nevro